Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
Madrigal Pharmaceuticals (MDGL) Stock Price & Analysis
970 Followers
MDGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$119.76 - $322.67
Previous Close$212.04
Volume625.15K
Average Volume (3M)570.23K
Market Cap
$4.67B
Enterprise Value$4.55B
Total Cash (Recent Filing)$232.35M
Total Debt (Recent Filing)$116.56M
Price to Earnings (P/E)-10.6
Beta1.00
Next Earnings
May 07, 2024EPS Estimate
-$6.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.93
Shares Outstanding19,897,425
10 Day Avg. Volume268,582
30 Day Avg. Volume570,233
Standard Deviation0.44
R-Squared0.00320
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)11.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.65
Forecast
1Y Price Target
$391.14Price Target Upside84.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageWith physicians planning to prescribe Rezdiffra to over half of their patients, it challenges the dominance of competing drugs and underscores the strong sales potential of Rezdiffra in the NASH market.
Drug Approval And Market PotentialRezdiffra is now available in the US as the first and only approved therapy to treat nonalcoholic steatohepatitis (NASH), potentially addressing a significant market of approximately 315,000 patients.
Sales And Market PenetrationAnalysts anticipate robust commercial coverage for Rezdiffra, expecting to reach around 80% of lives covered by year-end, which could significantly drive sales upward.
Bears Say
Financial PerformanceManagement expects a gradual launch for Rezdiffra and anticipates that the Gross-to-Net (GTN) adjustments will be choppy and normalize over time, suggesting potential initial volatility in revenue recognition.
Market Access ChallengesPayers are expected to implement rigorous coverage guidelines for resmetirom, potentially slowing patient access.
Pricing ConcernsThe $47k per patient per year price tag for Rezdiffra is at the higher end of cost-effectiveness analyses, which could result in commercial barriers.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $119.76 and its highest was $322.67 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2024 which is in 13 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Feb 28, 2024. The company reported -$5.68 earnings per share for the quarter, missing the consensus estimate of -$5.239 by -$0.441.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$6.23.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 20,993,578 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$5.68 in its last earnings report, missing expectations of -$5.239. Following the earnings report the stock price went up 6.018%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 456M.
---
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$391.14 (84.47% Upside)
$391.14 (84.47% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 15.6%
Last 30 Days ▲ 15.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.99%
12-Months-Change
Fundamentals
Return on Equity
-123.98%
Trailing 12-Months
Asset Growth
76.67%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Stock 12 Months Forecast
Average Price Target
$391.14
▲(84.47% Upside)
Technical Analysis
Amarin
―
Arrowhead Pharmaceuticals
―
Corbus Pharmaceuticals
―
Galmed Pharmaceuticals
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+113.28%
reiterated a buy rating last month
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +113.28% per trade.
---